Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 9/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707969 | 0.91 | FTO (0.46) | FTOBRD4ROCK1GRIK1BRD2 | |
| SCHEMBL6710311 | 0.88 | FTO (0.41) | FTOBRD4ROCK1CREBBPUSP30 | |
| SCHEMBL6710099 | 0.87 | HIF1A (0.35) | FTOBRD4ROCK1BRD2CREBBP | |
| SCHEMBL6708878 | 0.86 | ROCK1 (0.40) | FTOROCK1GRIK1KMT2ALMNA | |
| SCHEMBL6710340 | 0.84 | ROCK1 (0.39) | ROCK1GRIK1KMT2ALMNAHDAC6 | |
| SCHEMBL6710478 | 0.83 | MAPT (0.47) | KMT2ALMNA | |
| SCHEMBL6710127 | 0.83 | ROCK1 (0.47) | ROCK1GRIK1KMT2ALMNA | |
| SCHEMBL6709833 | 0.83 | MAPT (0.42) | GRIK1KMT2A | |
| SCHEMBL6714295 | 0.83 | GRIK1 (0.41) | ROCK1GRIK1USP30KMT2A | |
| SCHEMBL6710341 | 0.82 | ROCK1 (0.38) | ROCK1GRIK1KMT2AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | FTO 1216/4885BRD4 1588/4885ROCK1 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.